Following induction of general anaesthesia, the ulnar nerve was stimulated via surface electrodes at 2 Hz train-of-four stimuli every 20 seconds and the evoked compound adductor pollicis EMG was recorded (Relaxograph®, Datex, Helsinki, Finland). A cumulative dose-response curve for alcuronium was created by administering the drug as 50 or lOO jlg/kg increments until 95% neuromuscular block (NMB = depression of the first twitch height in the train-of-four responses) was established. Increments were given only after maximum twitch depression had occurred following the previous dose. The level ofNMB was plotted on log-probit paper and a cumulative doseresponse curve drawn by linear regression analysis. Individual ED50 and ED95 values of alcuronium and the slope of the dose-response curve were calculated. Subsequent alcuronium doses (15-20% of individual ED95 dose) were given every time the first twitch height recovered to > 10% of the calibration value. At the end of surgery, the residual NMB was antagonised by neostigmine 50 jlg/kg with atropine 20 jlg/kg. ED50 and ED95 doses for alcuronium were 208 and 440 jlg/kg, respectively and the slope of the dose-response curve was 5.0 probit/log. The alcuronium requirement to maintain an average 93% NMB during the 3.0 hour anaesthesia was 340 jlg/kg/h, 77% of his ED95 dose.
Case 2:
An eleven-year-old (34 kg) girl with a suprasellar cyst was anaesthetised and neuromuscular transmission monitored in the way described above. The child received diazepam 0.3 mg/kg as premedication. She did not have any other preoperative medication. A dose-response curve for alcuronium was created and subsequent small Twitch 100
-Neuromuscular blocking effect of a maintenance dose ofalcuronium (116 ofED9s dose) before and after the administration of a loading dose of phenytoin (20 mg/kg). Twitch height decreased from 11 to 3% and recovered to 11 % in 32 min before phenytoin. The same dose of alcuronium decreased twitch height from 11 to only 7% and twitch height recovered to 11 % in only 21 min following phenytoin. The maintenance requirement increased by 45% following phenytoin-infusion. increments given as described. Two and a half hours after induction of anaesthesia she received an intravenous loading dose of phenytoin 20 mglkg, given over 20 minutes. EDs and ED9S values for alcuronium were 135 and 2~8 J.1g1kg respectively, and the slope of the dose-response curve was 5.5 probit/log. Her alcuronium requirement to maintain an average 93% NMB was 70 and 102 J.1g1kglh before and following the administration of phenytoin, respectively. The alcuronium increment which was given at the time of phenytoin administration produced significantly less NMB than the other increments ( Figure 1 ). The duration of anaesthesia was 4.5 hours. Arterial carbon dioxide tension was maintained at 27-30 mmHg throughout the anaesthetic (arterial pH was 7.53-7.54). Plasma phenytoin concentration was 32 J.1g1ml (130 J.1mol/l) one hour after the administration of the drug. This is greater than a normal therapeutic concentration.
DISCUSSION This report suggests that the resistance which phenytoin produces to the neuromuscular blocking effects of pancuronium, I metocurine 2 and vecuronium 3 following chronic administration may also occur with alcuronium in bolus and short term administration. It is notable that resistance was not shown to atracurium 3 and that Gray, Slater and. Pollard demonstrated a statistically, but not clinically, significant potentiation of neuromuscular block with vecuronium. 4 Our patients demonstrate both that resistance may be produced immediately following a loading dose of phenytoin and that fully developed resistance may follow a short course of phenytoin therapy.
Our first child had 60% greater ED 9 ) dose than normal children (440 vs. 270 J.1g1kg) although the slope of his dose-response curve was normal. 5 This magnitude of increase for the dose-requirement is comparable to that found with vecuronium in adults. 3 His alcuronium requirement to maintain a 93% neuromuscular block was 340 J.1g1kglh, which is approximately three times the normal paediatric requirement. 6 This increase in requirement was greater than that shown previously with pancuronium l or metocurine. 2 Our second patient had normal ED-values and slope of the dose-response curve. These were determined before any phenytoin was given. The immediate effect on NMB of a loading dose of phenytoin was similar to that of anticholinesterase reversal. The maintenance requirement of alcuronium increased by 45% following the loading dose of phenytoin. This magnitude of resistance to alcuronium was greater than found when using vecuronium. 4 Several possible mechanisms have been proposed for the observed resistance to nondepolarizing neuromuscular blocking agents seen with phenytoin. 1,7 These include: (1) increased metabolism via enzyme induction; (2) decreased sensitivity at the receptor site; (3) an increase in receptor number; (4) increased end-plate anticholinesterase activity; or (5) a mechansim related to the membrane stabilising action. Phenytoin did not produce any pharmacokinetic change with metocurine and increased metabolism or elimination could not explain the resistance to this drug. 2 The immediate resistance following phenytoin in our case suggests enzyme induction is an unlikely factor. Phenytoin may produce resistance to different muscle relaxants via different mechanisms. 3 The greatly increased maintenance requirement of alcuronium may reflect phenytoin'S pre-junctional Anaesthesia and Intensive Care. Vo/. 18. No. 4. November. 1990 effects, since a1curonium is a more potent prejunctional receptor blocker than pancuronium. 8 It may be that the acute and the chronic phenytoin induced changes of the neuromuscular blocking effects of muscle relaxants also are produced by different mechanisms.
In summary, our two patients, who received either a short course of phenytoin or one loading dose of phenytoin, showed marked resistance to alcuronium induced neuromuscular block.
